Erythromycin A dihydrate 是由放线菌产生的大环内酯类抗生素 (antibiotic)，具有广泛的抗菌活性。Erythromycin A dihydrate 通过结合细菌的 50S 核糖体亚基而起作用，并通过阻断转肽和/或易位反应来抑制 RNA 依赖性蛋白 (RNA-dependent protein synthesis) 的合成，而不会影响核酸的合成。Erythromycin A dihydrate 在不同领域的研究中显示出抗肿瘤特性和保护神经的作用。
| 生物活性 | Erythromycin A dihydrate is amacrolideantibioticproduced byactinomycete Streptomyceserythreus with a broad spectrum of antimicrobial activity. Erythromycin A dihydrate binds tobacterial50S ribosomal subunits and inhibits RNA-dependent protein synthesis by blockage of transpeptidation and/or translocation reactions, without affecting synthesis of nucleic acid[1][2]. Erythromycin A dihydrate also exhibits antitumor and neuroprotective effect in different fields of research[3][4]. |
| IC50& Target | |
体外研究
(In Vitro) | Erythromycin A dihydrate inhibits growth ofP. falciparumwith IC50and IC90values of 58.2 μM and 104.0 μM, respectively[1].
Erythromycin A dihydrate (10 μM, 100 μM; 24 h, 72 h) shows antioxidant and anti-inflammatory effects and suppresses the accumulation of 4-HNE (p<0.01) and 8-OHdG (p<0.01), reduces Iba-1 (p<0.01) and TNF-α (p<0.01) expression significantly[4].
Cell Viability Assay[4] | Cell Line: | Embryos primary cortical neuron (from the cerebral cortices of 17-day-old Sprague-Dawley rat) | | Concentration: | 10, 100 μM | | Incubation Time: | 24, 72 hours | | Result: | Improved the viability of cultured neuronal cells in vitro after 3 hours oxygen-glucose deprivation (OGD). |
|
体内研究
(In Vivo) | Erythromycin A dihydrate (gastric intubation; 0.1-50 mg/kg; 30-120 days) decreases tumor growth and prolong the survival time of mice from dose of 5 mg/kg in mice[3].
Erythromycin A dihydrate (gastric intubation; 5 mg/kg) protects mice alive even at 120 days after inoculation, but shortens mean survival time in tumor-bearing mice by 4-5 days with dose of 50 mg/kg[3].
Erythromycin A dihydrate (i.h.; single injection; 50 mg/kg) has a protective effect on the rat model with cerebral ischemia reperfusion-injury[4].
| Animal Model: | Female ddY mice at the age of 6 weeks with EAC cells or CDF mice at the age of 6 weeks with P388 cells[3] | | Dosage: | 0.1 mg/kg; 0.5 mg/kg; 10 mg/kg; 30 mg/kg; 50 mg/kg | | Administration: | Gastric intubation; 30-120 days | | Result: | Decreased tumor growth and prolonged the mean survival time of mice from the dose of 5 mg/kg, however, the 50 mg/kg dosage shortened the MST in tumorbearing mice. |
| Animal Model: | Male Sprague-Dawley rats (8-week-old, 250-300 g)[4] | | Dosage: | 50 mg/kg | | Administration: | Subcutaneous single injection | | Result: | Reduced infarct volume and edema volume, improved neurological deficit. |
|
| Clinical Trial | |
| 分子量 | |
| Formula | |
| CAS 号 | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
m.cnreagent.com